Academic-Capital

San Diego’s has added another successful business to its budding biotech hub. Start-up firm aTyr Pharma, Inc. drew over $76 million investment capital from Sofinnova Ventures and another undisclosed entity to develop its drug called Resolaris that helps treat muscular dystrophy (Fikes, 2015). Biotech firms like aTyr help encourage greater investment and employment in the San Diego economy. Every investment opportunity comes with risk and rewards. Venture capitalists diligently assess whether the risks and rewards are worth investing their hard earned capital.   Risk tolerant investors are more likely to get involved in highly innovative startups (Tian & Wang, 2014). In this case, a single patentable and profitable drug can make or break the firm’s long-term future.   The ability to have exclusive rights to manufacture an important drug can be worth hundreds of millions of dollars. Approval of Resolaris for use and testing in the E.U., U.S. and other markets will add si